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1. Introduction 
Lactoperoxidase (LPO), a heme-containing oxidation-reduction enzyme present in milk and 
saliva, is part of an antimicrobial system, and converts thiocyanate to hypothiocyanate in a 
hydrogen peroxide-dependent reaction. The molecular weight of LPO is approximately 78 
kDa, and the carbohydrate moiety comprises about 10% of the total weight (Mansson-
Rahemtulla et al., 1988). LPO, myeloperoxidase (MPO), eosinophil peroxidase (EPO) and 
thyroid peroxidase (TPO) belong to the homologous mammalian peroxidase family and 
share 50 to 70% identity. Even higher homology can be found among their active site-related 
residues. These peroxidases can catalyze oxidation of halides and pseudohalides such as 
thiocyanate by hydrogen peroxide to form potent oxidant and bactericidal agents. MPO has 
been shown to inactivate influenza virus (Yamamoto et al., 1991) and HIV-1 virus (Klebanoff 
& Kazazi, 1995). Human recombinant MPO has been shown to have a virucidal effect on 
HIV-1 virus (Moguilevsky et al., 1992; Chochola et al., 1994) and cytomegalovirus (EI 
Messaoudi et al., 2002). However, few studies have examined whether LPO inhibits virus 
infection in vitro and in vivo. 
Lactoferrin (LF), also called lactotransferrin, is an iron-binding protein present in milk, 
saliva, tears, mucus secretions and secondary granules of neutrophils. Each LF molecule can 
bind 2 Fe (III) ions tightly but reversibly. This binding is dependent on concomitant binding 
of anions such as bicarbonate and carbonate, which play an essential role in holding the 
metal firmly (Masson et al., 1968). Thus, LF can exist in an iron-free (apo) or iron-bound 
(holo) state. LF is a prominent antimicrobial component of mucosal surfaces prone to attack 
by microbial pathogens. LF is actively secreted by neutrophils in the inflammatory response 
(Gutteberg et al., 1984). As an anti-microbial component of colostrum and milk, LF may play 
significant roles in protection of neonates from infectious diseases (García-Montoya et al., 
2011). The importance of LF in host defense is underlined by findings indicating that 
www.intechopen.com
 
Insight and Control of Infectious Disease in Global Scenario 
 
250 
patients with congenital or acquired defects of LF production exhibit an abnormal 
predisposition to recurrent infections by bacteria, fungi and parasites (Venge et al., 1984; 
Tanaka et al., 1996). Patients with acute viral illnesses such as chickenpox, measles, rubella, 
hepatitis or Epstein-Barr virus infection have reduced plasma LF concentrations, although 
their total neutrophil numbers are similar to those of non-infected subjects (Bayners et al., 
1986). 
Vaccinia virus belongs to the family of poxviridae, and is the most intensively studied 
member of the poxvirus family (Moss et al., 1990). Poxviruses replicate in the cytoplasm of 
infected cells without using nuclear enzymes of the host cells for transcription or DNA 
synthesis. Vaccinia virus has circumvented the need for nuclear enzymes by encoding or 
packaging a complete enzyme system for transcription (Moss et al., 1990) and DNA 
synthesis, including a DNA-dependent DNA polymerase (Moss & Cooper, 1982), DNA 
topoisomerase (Shuman et al., 1987) and DNA ligase (Kerr et al., 1989). Consequently, the 
vaccinia virus is widely used as an expression system in molecular biotechnology. 
Recombinant vaccinia virus has been demonstrated to be an effective antigen delivery 
system for infectious diseases in many species, with rabies and rinderpest being notable 
examples (Ertl and Xiang, 1996; Tsukiyama et al., 1989). In addition recombinant vaccinia 
virus can give rise to long-term immunity (Inui et al., 1995). In previous studies, 
recombinant vaccinia virus has been used produce cytokines (e.g., IFN-, IFN-) (Kohonen-
Corish et al., 1989, 1990; Peplinski et al., 1996; Nishikawa et al., 2000, 2001), but it has not yet 
been used for expression of bovine LPO (bLPO) or bovine LF (bLF). In the present study, we 
constructed recombinant vaccinia viruses that express bLPO and bLF with antiviral activity, 
and characterized production of bLPO and bLF and replication of the recombinant virus. 
The present results indicate that expression of bLPO and bLF by recombinant vaccinia virus 
may be useful for treatment of infectious diseases in humans or animals (Tanaka et al., 
2006). 
2. Materials and methods 
2.1 Cells and viruses 
Rabbit kidney (RK13) cells were cultured in Eagle’s minimum essential medium (EMEM, 
Sigma Chemicals Co., St. Louis, MO, USA) supplemented with 8% heat-inactivated fetal 
bovine serum (FBS). Vaccinia virus LC16mO (mO) strain and its recombinant were 
propagated in RK13 cells in EMEM supplemented with 8% FBS. 
2.2 Construction of recombinant vaccinia virus that expresses bLPO and bLF 
bLPO or bLF cDNA was amplified from mammary gland cells, using reverse polymerase 
chain reaction (RT-PCR) with primers designed from bLPO or bLF cDNA (Dull et al., 1990; 
Nakamura et al., 2001). The PCR products were blunted by T4 DNA polymerase and ligated 
with the vaccinia virus transfer vector pAK8 (Yasuda et al., 1990), which was cut with Sal I 
and then blunted. The plasmid (pAK/bLPO or pAK/bLF) was transfected into RK13 cells 
using a lipofectin reagent (Life Technologies Japan, Tokyo, Japan) for 1 h after infection with 
the mO strain. After 2 days of incubation, culture medium was collected. We isolated 
recombinant virus (vv/bLPO or vv/bLF) produced by homologous recombination between 
www.intechopen.com
Expression and Characterization  
of Bovine Milk Antimicrobial Proteins Lactoperoxidase and Lactoferrin by Vaccinia Virus 
 
251 
pAK8 and viral thymidine kinase (TK-) cells in the presence of 100 g/ml 5-bromo-2’-
deoxyuridine, selecting TK- viruses by plaque isolation. 
2.3 Immunofluorescence test (IFAT) 
RK13 cells were infected with mO, vv/bLPO and vv/bLF (5 plaque-forming units 
[PFU]/cell, 48 h), and subjected to indirect immunofluorescence assay test (IFAT). The 
infected RK13 cells were fixed with acetone, and incubated with mouse anti-bLPO 
monoclonal antibody (anti-bLPO mAb) or mouse anti-bLF monoclonal antibody (anti-bLF 
mAb); these antibodies were produced by the present authors (Shimazaki et al., 1998; 
Watanabe et al., 1998). The cells were then stained with fluorescein-conjugated goat anti-
mouse antibody (Southern Biotechnology Associates Inc., Birmingham, AL, UK) or 
fluorescein-conjugated sheep anti-rabbit antibody (Waco Pure Chemical, Osaka, Japan). The 
cells were observed using fluorescence microscopy. 
2.4 Sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
western blot analysis 
RK13 cells in tissue culture (colony diameter, 15 mm) were infected with the mO strain or 
the recombinant vaccinia virus at a multiplicity of infection (moi) of 5 for 1 h at 37C. Then, 
the cells were washed with EMEM and cultured in 500 l of EMEM at 37C for 48 h. The cell 
extracts and culture supernatants were subjected to SDS-PAGE (Laemmli, 1970) under 
reducing conditions, followed by electrical transfer of proteins to a PVDF membrane 
(Osmonics Inc., Westborough, MA, USA). The membrane was immersed in blocking buffer 
(phosphate-buffered saline [PBS] containing 3% bovine serum albumin) at 4C overnight, 
incubated with rabbit anti-bLPO polyclonal antibody (anti-bLPO Ab) or anti-bLF mAb 
(diluted in the blocking buffer) at 37C for 1 h, washed 3 times with PBS, and then incubated 
with alkaline phosphatase-conjugated goat anti-rabbit IgG antibodies (Promega Co., 
Madison, WI, USA) or horseradish peroxidase-conjugated goat anti-mouse IgG antibodies 
(Waco Pure Chemical, Osaka, Japan) (diluted in the blocking buffer) at 37C for 1 h. The 
membrane was visualized by incubation with BCIP/NBT color substrate (Promega Co.) or 
0.5 mg/ml diaminobenzidine and 0.005% H2O2. 
2.5 Tunicamycin treatment 
Recombinant vaccinia virus-infected RK13 cells (5 PFU/cell) were incubated in EMEM 
containing 1 g/ml tunicamycin (Sigma Chemical Co.), which prevents synthesis of N-
linked sugars, for 1 to 48 h post-infection (pi). The cells were then harvested, and the cell 
lysate was subjected to Western blot analysis to assay for expression of recombinant 
proteins. 
2.6 Virus growth analysis 
RK13 cells were infected with mO or recombinant viruses at a moi of 5 PFU/cell. After 1 h, 
the infected cells were washed with EMEM and cultured for 12-72 h after viral infection. 
Virus titers were determined by plaque titration according to Nishikawa et al. (2000). Data 
from this experiment were evaluated using Student’s t-test. The 95% level of significance 
was used in the analysis. 
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3.1 Expression of bLPO and bLF by recombinant vaccinia virus in RK13 cells 
Vaccinia virus mO strain and pAK/bLPO or pAk/bLF were allowed to infect RK13 cells, 
and virus-containing medium of the infected RK13 cells was collected and analyzed by IFAT 
or Western blotting for the presence of recombinant bLPO or bLF. A recombinant bLPO or 
bLF-expressing clone was selected by the plaque-assay technique. vv/bLPO-infected cells 
were examined by IFAT and reacted with anti-bLPO mAb (Fig. 1B). Anti-bLF mAb reacted 
with vv/bLF-infected RK13 cells (Fig. 1C). mO-infected cells served as negative reference 
and were labeled with both antibody reagents (Fig. 1A). Recombinant bLPO and bLF were 
detected in cell extracts by Western blot analysis using anti-bLPO Ab and anti-bLF mAb 
(Fig. 2A, C lane 4). Recombinant bLPO and bLF were secreted into supernatants, as 
indicated by recombinant bLPO bands at 88 and 90 kDa and bLF band at 80 kDa (Fig.2B, D 
lane 4). The apparent molecular weight of these recombinant bLPO molecules (88 and 90 
kDa) was greater than that of native bLPO (78 kDa), but apparent molecular weight of the 
bLF molecules (80 kDa) was equal to that of native bLF (80 kDa). To test whether the 
increase of molecular weights in recombinant bLPO was due to glycosylation, the infected 
cells were treated with tunicamycin. As a result, no protein was secreted into the 
supernatant by infected cells treated with tunicamycin (data not shown). In the cell extracts, 
the apparent molecular weight of bLPO was reduced to 80 kDa (Fig. 3 lane 4), indicating 
that recombinant bLPO were modified by N-linked sugars. The 90 kDa molecule would be a 
proprotein. Recombinant bLF was not detected in cell extracts from infected cells treated 
with tunicamycin, suggesting that tunicamycin treatment completely abolished production 





Fig. 1. Immunofluorescence analysis of vv/bLPO and vv/bLF expressed in RK 13 cells. (A) 
mO-infected RK13 cells reacted with anti-bLPO mAb and anti-bLF mAb. (B) vv/bLPO-
infected RK13 cells reacted with anti-bLPO mAb. (C) vv/bLF-infected RK13 cells reacted 
with anti-bLF mAb. 
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Fig. 2. Western blot analysis of bLPO (A, B) and bLF (C, D) in RK13 cells. Cell extracts (A, C) 
and culture supernatants (B, D) of RK13 cells infected with recombinant vaccinia virus were 
analyzed using anti-bLPO Ab or anti-bLF mAb. Lane 1, RK13 cells; lane 2, mO-infected 
RK13 cells; lane 3, vv/green florescence protein-infected RK13 cells; lane 4, vv/bLPO- or 
vv/bLF-infected RK13 cells; lane 5, native bLPO or bLF (2 g). Molecular weights of marker 
proteins are given in kDa. 
 





Fig. 3. Western blot analysis of bLPO in RK13 cells treated with tunicamycin. Cell extracts of 
RK13 cells infected with recombinant vaccinia virus were analyzed using anti-bLPO Ab. 
Lane 1, mO-infected RK13 cells; lane 2, mO-infected RK13 cells treated with tunicamycin; 
lane 3, vv/bLPO-infected RK13 cells; lane 4, vv/bLPO-infected RK13 cells treated with 
tunicamycin; lane 5, native bLPO (2 g). Molecular weights of marker proteins are given in 
kDa. 
3.2 Time course of bLPO and bLF production in the recombinant vaccinia virus 
system 
To analyze the kinetics of expression of bLPO and bLF gene products, culture supernatants 
from RK13 cells infected with vv/bLPO and vv/bLF were collected from 12-72 h pi. 
Recombinant bLPO and bLF were first detectable in culture supernatant at 24 h pi (Fig. 4 
lane 2). The amount of recombinant bLPO and bLF increased from 36 to 48 h pi, and reached 
plateau levels by 72 h pi (Fig. 4 lane 3-6). 
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Fig.4. Kinetics of rbLPO (A) and rbLF (B) synthesis. RK13 cells were infected with 
recombinant vaccinia virus and harvested at 12 (lane 1), 24 (lane 2), 36 (lane 3), 48 (lane 4), 60 
(lane 5) and 72 hours pi (lane 6). Lane 7, native bLPO or bLF (2 g). Culture supernatants of 
infected RK13 cells were analyzed by Western blotting using anti-bLPO Ab or anti-bLF 
mAb. Molecular weights of marker proteins are given in kDa. 
3.3 Growth analysis of vv/bLPO and vv/bLF in RK13 cells 
The growth curves of mO, vv/bLPO and vv/bLF are compared in Fig. 5. Peak titers 
(reached at 48 h pi) of mO, vv/bLPO and vv/bLF were 1.6105, 1.6105 and 0.2105 PFU/ml, 
respectively. These results indicate that bLF, but not bLPO, inhibits growth of recombinant 
virus in infected RK13 cells. There were no significant differences in growth between mO 
and vv/bLPO until 72 h pi (P>0.05, Student’s t test mO vs. vv/bLPO). However, there were 
significant differences in growth between mO and vv/bLPO on one side and vv/bLF on the 
other side 48h pi through 72 h pi (P<0.05, Student’s t test mO or vv/bLPO vs. vv/bLF). 
 
 
Fig. 5. Virus growth analysis. RK13 cells were infected with mO (○), vv/bLPO (▵) and 
vv/bLF (□) at a moi of 5. Samples were harvested at the indicated time points, and progeny 
virus of RK13 cells was titered in triplicate.  
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The expression systems using recombinant baculovirus or Chinese hamster ovary cells have 
been used to express bLPO (Tanaka et al., 2003; Watanabe et al., 1998). However, there have 
been no previous reports of use of vaccinia virus to express bLPO and bLF. The available 
evidence suggests that growth of vaccinia virus is inhibited by expression of bLPO and bLF. 
In the present study, recombinant vaccinia viruses expressing bLPO or bLF (vv/bLPO and 
vv/bLF, respectively) were constructed. RK13 cells were infected with vv/bLPO or vv/bLF, 
and we characterized virus growth and post-translation modifications of the resultant 
product. 
Recombinant bLPO extracted from cell extracts and culture supernatants had an apparent 
molecular weight of 88 and 90 kDa, which is greater than that of native bLPO (78 kDa) in 
Western blot analysis. These size differences may be due to a difference in glycosylation 
level and differences in processing between RK13 cells and the mammary gland. When 
the infected RK13 cells were treated with tunicamycin, the apparent molecular weight of 
recombinant bLPO in the cells was 80 kDa, suggesting that recombinant bLPO is modified 
by N-linked glycosylation. Tunicamycin treatment completely abolished secretion of 
bLPO, indicating that N-linked glycosylation is essential for bLPO secretion. Therefore, 
recombinant bLPO was differentially processed during synthesis and secretion from RK13 
cells compared with the mammary gland. A similar situation was previously reported for 
recombinant bLPO expressed in insect cells (Tanaka et al., 2003). Interestingly, the 
molecular weight of recombinant bLPO produced in RK13 cells was higher than that 
expressed in insect cells. The carbohydrate structure analysis of purified recombinant 
bLPO expressed in insect cells and native bLPO found different reactivity with PHA-E4, 
PNA, and RCA120 by using lectin assay (Tanaka et al., 2003). Therefore, the glycosylation 
level of recombinant protein might also be different between RK13 cells and insect cells. 
Most of the bLPO extracted from milk showed Asp-101 as the N-terminal amino acid 
residue (Dull et al., 1990; Watanabe et al., 2000). However, Watanabe et al. (2000) found 
also that different preparations of bLPO showed a different N-terminal amino acid 
residue. These variations may result from differences in the disk-electrophoresis and ion-
exchange chromatography methods used for analysis (Carlström, 1969). Thus, it might be 
possible that the 90 kDa form of recombinant bLPO did not undergo proteolysis, whereas 
the 88 kDa form of recombinant bLPO be the result of proteolysis of some N-terminal 
amino acid residues during synthesis and secretion by RK 13 cells as observed for bLPO 
synthesized by the mammary gland.  
Bovine Lactoferrin is a 80 kDa iron-binding glycoprotein found in physiological fluids of 
mammals. bLF has also an antimicrobial activity as bLPO, and presumably contributes to 
the protective functions of milk against infectious diseases. In RK13 cells infected with 
vv/bLF, recombinant bLF was detected in both cell extracts and culture supernatants. 
However, the replication of vv/bLF at a moi of 5 PFU/cell was inhibited by the antiviral 
activity of recombinant bLF, suggesting that vv/bLF has an antiviral effect against vaccinia 
virus. On the other hand, the expression of bLPO was also detected in cell extracts and 
culture supernatants of the vv/bLPO-infected cells as well as vv/bLF-infected cells. 
However, the replication of vv/bLPO at a moi of 5 PFU/cell was not inhibited by antiviral 
activity of recombinant bLPO, because LPO catalyzes oxidation of endogenous thiocyanate 
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(SCN-) to produce hypothiocyanate (OSCN-) only in the presence of hydrogen peroxide 
(H2O2). These products have a broad-spectrum antimicrobial and antiviral activity (Shin et 
al., 2001, 2005). Therefore due to the absence of thiocyanate (SCN-) and/or hydrogen 
peroxide (H2O2) the replication of recombinant virus is not inhibited by recombinant bLPO.  
Studies indicate that gene therapy using viral vectors containing the bLPO gene can produce 
anti-microbial and anti-tumor activity (Odajima et al., 1996; Stanislawski et al., 1989). The 
major problem with such viral vectors is their attenuation. The recombinant vaccinia viruses 
in this report are TK- in phenotype that may reduce pathogenicity in vivo (Buller et al., 1985) 
because of insertion of the bLPO gene into the TK gene. Our results demonstrate the 
attenuation of the viral pathogenicity by introduction of the bLPO gene into vaccinia virus. 
Thus fine tuning of bLPO activity, may allow the control of virulence of vaccinia virus 
vector necessary for medical and veterinary applications in vivo. 
5. Conclusion 
Lactoperoxidase (LPO) is a 78 kDa heme-containing oxidation-reduction enzyme present in 
milk, and lactoferrin (LF) is an 80 kDa iron-binding glycoprotein found in physiological 
fluids of mammals. LPO and LF have antimicrobial activity, and presumably contribute to 
the protective functions of milk against infectious diseases. In this study, recombinant 
vaccinia viruses expressing bovine lactoperoxidase (vv/bLPO) or bovine lactoferrin 
(vv/bLF) were constructed. In rabbit kidney (RK13) cells infected with vv/bLPO or vv/bLF, 
recombinant bLPO or bLF was detected in both cell extracts and supernatants. Growth of 
vv/bLPO at a multiplicity of infection was not inhibited by antiviral activity of recombinant 
bLPO, indicating that this recombinant virus could be used as a suicide viral vector. 
Unfortunately, growth of vv/bLF at a multiplicity of infection was inhibited by antiviral 
activity of recombinant bLF, suggesting that vv/bLF has an antiviral effect against vaccinia 
virus. These results indicate that a combination of bLPO and vaccinia virus vector may be 
useful for medical and veterinary applications in vivo. 
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